The estimated Net Worth of Julian Baker is at least $4.75 Milion dollars as of 1 August 2012. Mr. Baker owns over 10,000 units of Incyte stock worth over $4,188,044 and over the last 21 years he sold INCY stock worth over $0. In addition, he makes $559,695 as Lead Independent Director at Incyte.
Julian has made over 3 trades of the Incyte stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of INCY stock worth $56,700 on 1 August 2012.
The largest trade he's ever made was buying 300,000 units of Incyte stock on 1 November 2004 worth over $2,925,000. On average, Julian trades about 11,667 units every 105 days since 2003. As of 1 August 2012 he still owns at least 66,340 units of Incyte stock.
You can see the complete history of Mr. Baker stock trades at the bottom of the page.
Julian C. Baker is Lead Independent Director of Incyte Corporation. Mr. Baker is a Managing Partner of Baker Brothers Investments, which he and his brother, Felix Baker, Ph.D., founded in 2000. Baker Brothers Investments is an investment advisor focused on long term investments in life sciences companies. Mr. Baker's career as a fund manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch family. Previously, Mr. Baker was employed from 1988 to 1993 by the private equity investment arm of Credit Suisse First Boston Corporation.
As the Lead Independent Director of Incyte, the total compensation of Julian Baker at Incyte is $559,695. There are 13 executives at Incyte getting paid more, with Herve Hoppenot having the highest compensation of $15,151,200.
Julian Baker is 53, he's been the Lead Independent Director of Incyte since 2015. There are 19 older and 5 younger executives at Incyte. The oldest executive at Incyte Corp. is Pamela M. Murphy, 70, who is the VP of Investor Relations & Corp. Communications.
Julian's mailing address filed with the SEC is , , , , .
Over the last 21 years, insiders at Incyte have traded over $114,417,378 worth of Incyte stock and bought 24,211,970 units worth $713,884,116 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B... a Brothers Life Sciences Capi.... On average, Incyte executives and independent directors trade stock every 14 days with the average trade being worth of $4,355,654. The most recent stock trade was executed by Steven H Stein on 12 August 2024, trading 11,608 units of INCY stock currently worth $703,793.
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
Incyte executives and other stock owners filed with the SEC include: